Blood Tests That Promise to Detect Cancer: Why You Should Be a Skeptic, Not a Consumer

Read Time: 6 min

During the Super Bowl in February 2026, tens of millions of Americans were shown an advertisement that I found deeply troubling — not because it was dishonest in an obvious way, but because it was misleading in a way that requires scientific context to recognize. The ad, promoting the Galleri multi-cancer early detection blood test through the direct-to-consumer health platform Hims & Hers, showed a man exhaling with visible relief as he looked at his phone and read the words “No cancer signal detected.” The implication was clear: the test had checked, found nothing, and the man could breathe easy. What the advertisement did not mention is that, in the largest published study of the Galleri test, its overall sensitivity was approximately 51.5% — meaning that a result reading “no cancer signal detected” could be wrong roughly half the time.

A diagnostic tool that misses cancer in half the cases where cancer is present does not give patients peace of mind; it gives them false reassurance, which is a medically and ethically different thing entirely. And yet the test is now being sold directly to consumers for $750 above the standard subscription price, marketed with the emotional power of a Super Bowl stage and the implicit credibility that attaches to any product willing to spend that kind of money advertising itself.

The Pattern Behind the Promise

The blood test industry has been promising a revolution in cancer detection for years, and it is worth understanding the difference between a plausible scientific hypothesis and a proven medical intervention. The hypothesis is sound and genuinely exciting: if cancers shed detectable fragments of their genetic material into the bloodstream early in their development, then a sensitive blood test might catch them before they become symptomatic, improving survival outcomes dramatically. Decades of epidemiological evidence support the premise that early detection, for many cancer types, correlates with better survival. The question is not whether the idea is good. The question is whether any specific test, right now, actually delivers on that idea with sufficient accuracy to justify widespread use.

The answers to that question require three distinct forms of evidence. Analytical validity asks whether the test reliably measures what it claims to measure. Clinical validity asks whether a positive result actually predicts the presence of cancer in a meaningful way across diverse populations. And real-world benefit asks whether using the test leads to earlier treatment that improves health outcomes, rather than triggering invasive follow-up procedures for false positives while missing true positives at an unacceptable rate. For most of these tests currently marketed to consumers, robust evidence satisfying all three criteria does not yet exist.

Theranos Was a Warning, Not an Anomaly

The most instructive precedent for evaluating the current blood test landscape is Theranos, the company that raised billions of dollars on the promise that a few drops of blood could reliably diagnose hundreds of conditions, moved directly from device development into consumer testing before demonstrating the basic forms of scientific validity described above, and ultimately collapsed under the weight of evidence that its technology did not work as advertised. The Theranos story is often told as a story of individual fraud, but it is more usefully understood as a story about what happens when regulatory oversight fails to keep pace with marketing ambition in the consumer health space.

A recent enforcement action by the Securities and Exchange Commission against Cancer Check Labs suggests the pattern has not disappeared. The SEC alleges that investors were told their funds would support clinical research and regulatory approval for a blood-based cancer screening device; more than $10 million was instead diverted for personal spending and unrelated ventures. The complaint describes bold scientific claims, vague regulatory promises, and little evidence that the underlying technology performed as advertised — a template that should by now be familiar to anyone who has followed this space closely.

I want to be careful not to conflate different kinds of wrongdoing. Securities fraud and medical fraud are legally distinct, and not every company selling blood tests is engaged in deliberate deception. But the structural incentives that make consumer health testing susceptible to abuse — the combination of genuine public anxiety about cancer, deep scientific complexity that most consumers cannot independently evaluate, and regulatory frameworks that sometimes permit marketing to outpace evidence — are the same across cases. The fraud is a symptom. The underlying disease is a regulatory environment that has not kept pace with the commercialization of diagnostic testing.

What Good Evidence Looks Like, and Why It Matters

The United Kingdom’s National Health Service is currently running a randomized controlled trial of more than 140,000 people to evaluate whether the Galleri test actually reduces the incidence of late-stage cancer and cancer death, with results expected later this year. That is what rigorous evidence generation looks like: a large, diverse population, a prospective design, clinical endpoints that matter to patients, and results that have not yet been announced, which means no one yet knows whether the test will pass or fail.

If the NHS trial demonstrates clear benefit, that will be genuinely important news, and it will substantially change the evidentiary case for broad adoption of this technology. Until then, my strong advice to anyone considering one of these tests is to have an honest conversation with a physician you trust before spending money on a product whose benefits, in most populations, remain unproven. The existence of a blood test on the market does not mean the test has been proven accurate, useful, or safe. Marketing is not evidence. Relief visible on a face in a Super Bowl ad is not a clinical endpoint. And peace of mind built on a result that may be wrong half the time is not peace of mind at all.

Cancer is serious enough to deserve better than that. So are you.